Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05962840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to investigate the remission rate of patients treated with Telitacicept combined with Rituximab in remission-induction and Telitacicept alone in remission-maintain treatment.
Trial Details
NCT Number NCT05962840
Lead Sponsor Chinese SLE Treatment And Research Group
Collaborators: Peking Union Medical College Hospital
Conditions
(from sponsor)		 ANCA Associated Vasculitis
Related terms Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov